Brought to you by 
Lundbeck partners shelved insomnia agent gaboxadol with Ovid in two new indications
08 May 2017
Executive Summary
H. Lundbeck AS licensed Ovid Therapeutics Inc. exclusive worldwide rights to develop and sell the highly selective extrasynaptic GABA-A agonist gaboxadol for the orphan diseases Angelman and Fragile X syndromes. Ovid renamed the candidate OV101.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Lundbeck partners shelved insomnia agent gaboxadol with Ovid in two new indications
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice